AMG 133 is a bispecific molecule that addresses two targets, GLP-1 and GIPR, and in a phase 1 study achieved clinically significant body weight reductions over 12 weeks in people with obesity and ...

MariTide (formerly AMG 133). While the study demonstrated notable weight-loss potential, investor expectations for the drug's efficacy may have been higher, contributing to the stock's decline.

MariTide (maridebart cafraglutide; formerly AMG 133) hit the headlines in May after Amgen management expressed its excitement about the GLP-1 and GIP-directed bispecific antibody in its first ...